Dana Investment Advisors Inc. boosted its holdings in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) by 7.5% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 201,538 shares of the biopharmaceutical company’s stock after buying an additional 14,089 shares during the quarter. Dana Investment Advisors Inc. owned approximately 0.43% of Sucampo Pharmaceuticals worth $2,378,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in SCMP. Argent Capital Management LLC acquired a new stake in shares of Sucampo Pharmaceuticals during the third quarter valued at about $1,067,000. Point72 Asset Management L.P. acquired a new stake in shares of Sucampo Pharmaceuticals during the third quarter valued at about $21,989,000. Royce & Associates LP boosted its stake in shares of Sucampo Pharmaceuticals by 9.7% during the third quarter. Royce & Associates LP now owns 1,171,731 shares of the biopharmaceutical company’s stock valued at $13,826,000 after purchasing an additional 103,808 shares in the last quarter. Hartford Investment Management Co. acquired a new stake in shares of Sucampo Pharmaceuticals during the third quarter valued at about $165,000. Finally, Schwab Charles Investment Management Inc. boosted its stake in shares of Sucampo Pharmaceuticals by 19.2% during the third quarter. Schwab Charles Investment Management Inc. now owns 294,181 shares of the biopharmaceutical company’s stock valued at $3,472,000 after purchasing an additional 47,385 shares in the last quarter. 65.31% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages have recently commented on SCMP. BidaskClub raised Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. ValuEngine raised Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, December 7th. Mizuho lifted their price target on Sucampo Pharmaceuticals from $12.00 to $14.00 and gave the company a “neutral” rating in a research note on Friday, December 8th. Maxim Group set a $23.00 price objective on Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, December 7th. Finally, B. Riley raised their price objective on Sucampo Pharmaceuticals from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, December 6th. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $16.60.

Sucampo Pharmaceuticals, Inc. (SCMP) opened at $16.75 on Friday. Sucampo Pharmaceuticals, Inc. has a 1 year low of $9.30 and a 1 year high of $17.70. The company has a debt-to-equity ratio of 7.37, a quick ratio of 4.46 and a current ratio of 5.11. The stock has a market capitalization of $769.49, a PE ratio of 11.30, a PEG ratio of 4.91 and a beta of 1.47.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.25 by $0.02. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The company had revenue of $61.27 million during the quarter, compared to the consensus estimate of $58.05 million. During the same period last year, the company earned $0.30 earnings per share. The firm’s revenue was up 5.9% compared to the same quarter last year. research analysts predict that Sucampo Pharmaceuticals, Inc. will post 1.12 EPS for the current fiscal year.

In other news, insider Peter A. Kiener sold 50,000 shares of the firm’s stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $16.50, for a total transaction of $825,000.00. Following the completion of the transaction, the insider now directly owns 52,023 shares in the company, valued at $858,379.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.13% of the stock is owned by company insiders.

WARNING: This piece of content was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://theolympiareport.com/2017/12/15/sucampo-pharmaceuticals-inc-scmp-shares-bought-by-dana-investment-advisors-inc.html.

Sucampo Pharmaceuticals Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Want to see what other hedge funds are holding SCMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP).

Institutional Ownership by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.